Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi‐center retrospective case series. Issue 6 (19th September 2020)

• Record Type: Journal Article
• Authors: Ari, Anne; Levy, Yael; Segal, Nirit; Maoz‐Segal, Ramit; Benor, Shira; Broides, Arnon; Horev, Amir; Epstein‐Rigbi, Na'ama; Agmon‐Levin, Nancy; Marcus, Nufar
• Is Part Of: Pediatric dermatology. Volume 37:Issue 6(2020)
• Page Start: 1051
• Page End: 1054
• Publication Date: 2020-09-19
• Subjects: chronic urticaria -- omalizumab -- pediatric chronic urticaria -- recalcitrant urticaria; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.14360
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Background: Chronic urticaria is defined by the presence of itchy wheals, sometimes accompanied by angioedema, lasting for at least 6 weeks. In children, most cases occur without an eliciting factor and are defined as chronic spontaneous urticaria (CSU). CSU affects up to 0.75% of children with a negative impact on quality of life and school performance. CSU is treated in adults with second‐generation antihistamines, increased up to four times normal doses for second‐line treatment. Omalizumab (a monoclonal antibody to IgE) may be recommended as third‐line therapy. A similar protocol is used in children, yet little is known of its efficacy and safety. Objectives: To summarize our multi‐center experience in treating children with recalcitrant CSU with omalizumab. Methods: A retrospective multi‐center case series conducted in 5 tertiary care centers in Israel. Patients included were children <18 years old diagnosed with recalcitrant CSU who were treated with omalizumab. Patients were followed up throughout the duration of omalizumab therapy/symptom remission. Patients' electronic medical records were used to gather data. Results: Nineteen participants (11 F; 8 M) presented with CSU between ages 6 and 16.9 years. Sixteen (84%) responded to omalizumab, including children <12 years old, although two became non‐responsive after 6‐12 months of therapy. Another three patients (16%) were resistant to treatment, achieving remission through fourth‐line (Cyclosporine A) or other therapies. Conclusion: Children with recalcitrant CSU, even those <12 years old, respond well to standard‐dose, third‐line omalizumab therapy at rates similar to adults. Yet, some cases may become non‐responsive with ongoing treatment.